Two continents, two firms, one investment thesis. That is the short version of Yazan al Homsi’s career. The longer version explains why his name keeps turning up next to small-cap clean-tech and healthcare AI companies years before they become household names, and why two of his portfolio companies just posted a run of milestones in the same month. It also explains why coverage of him tends to read more like a due-diligence memo than a personality profile, which is probably how he’d prefer it, given how consistently he and his firms frame every relationship as an investment rather than a partnership.
Disclosure, stated upfront rather than buried at the bottom: al Homsi holds equity in the companies named in this piece, including Aduro Clean Technologies and Rocket Doctor AI. That’s the plainest way to say it, and it’s said here directly because it’s the whole reason his read on either company is worth anything.
Background and Early Career
Al Homsi was born in Saudi Arabia and moved to Canada at age 11, bouncing between Toronto and Montreal before heading back to Saudi Arabia to finish high school. He returned to Montreal for McGill University, graduating in 2004 with a finance degree, top 5 percent of his class, plus a six-month internship at General Motors under his belt. That early life and career path is a fairly conventional finance-track resume up to this point, which makes what came next more interesting.
Before finance fully took hold, al Homsi worked as a sales rep at Imperial Oil in Toronto for about 18 months, then co-founded a Montreal cafe-bistro, Cafe Noir, running it for 14 months. Staffing, operations, customer service: the basics of running a small business, learned firsthand rather than from a case study. It’s an unusual detour for someone who ends up running two venture firms, but it shows up in how he talks about management quality today: he’s someone who has actually had to make payroll, not just model it in a spreadsheet.
From PwC to Founders Round Capital
The real training ground was PricewaterhouseCoopers, where al Homsi spent more than ten years across Saudi Arabia and the UAE. Starting as a senior consultant in M&A and IPO advisory, he rose to senior manager and then director, running due diligence and valuation work across retail, real estate, distribution, manufacturing and healthcare. He picked up his CFA charter along the way, and the habits from that decade, especially an insistence on direct relationships with management teams rather than a purely numbers-driven review, show up repeatedly in how he describes his venture screening process today. It’s the same instinct that later shaped how he evaluates management teams at Aduro and Rocket Doctor AI: less interested in the pitch deck, more interested in whether the people running the company can actually execute on it.
The deal that gets cited most often from this era is Medicago, the Canadian vaccine developer that al Homsi was involved with early on. It grew from under US$10 million in market cap to US$357 million before Mitsubishi Pharma and Philip Morris came calling in 2013, an outcome that has anchored much of his early-stage reputation ever since.
2017: al Homsi launches Founders Round Capital in Vancouver’s innovation ecosystem, targeting small-cap companies on the path from private to public markets. 2018: he adds Catalyst Communications DMCC in Dubai, building a bridge between Middle Eastern capital and North American startups. He has run both firms since, splitting time between the two cities. In between, he was active during Canada’s 2016 to 2018 cannabis legalization window, advising companies in the sector with the same preference, sustainable business models over speculative license plays, that is reflected in how he talks about clean tech and healthcare AI today.
The Portfolio Today
Today’s portfolio leans into two sectors: clean technology, through Aduro Clean Technologies, and healthcare AI, through Rocket Doctor AI, a physician marketplace built around AI-assisted patient intake. In both cases, al Homsi is an investor, not an operator or partner in the businesses. His screening criteria, by his own description: strong IP, big addressable markets, proven management, and a real market failure the technology is built to fix.
On the clean-tech side, Aduro has spent the past month backing up that thesis with actual data: an 86 percent liquid hydrocarbon recovery rate from its pilot plant, followed two weeks later by a combined US$22.2 million raised across two offerings, both priced clean with no warrants attached. On the healthcare AI side, Rocket Doctor AI has reported fiscal 2025 revenue of $1.74 million, gross margins near 87 percent, and a payer network topping 21 million U.S. in-network members, proof points from two very different industries that both fit the same investment mold. It’s worth remembering that in both cases al Homsi is the capital and screening partner, not the operator, a distinction his own materials are consistent about.
Al Homsi has also picked up recognition for pushing ESG considerations into venture investing specifically, rather than treating it as a separate category from financial performance. A 2024 profile in The American Reporter placed him among investors driving that shift, a framing that has followed him into subsequent coverage of his AI and ESG transformation work across Aduro and Rocket Doctor AI. Look across his career and the same shape keeps repeating: a documented problem, a regulatory or economic tailwind already pushing toward a fix, and a management team he’s willing to bet can execute. Medicago in biotech, cannabis operators in 2016 to 2018, Aduro in chemical recycling, Rocket Doctor AI in virtual care. Different industries, same test applied each time.
It is a resume built on due diligence rather than headlines, which may be exactly why it took this long for anyone to write it up. Additional background on his own site tracks with the same story: two firms, two continents, one repeated screening process, applied to whatever sector currently has a documented gap worth closing. Two of his companies just gave the press a reason to pay attention, and whether that attention holds past this news cycle probably depends less on al Homsi’s biography and more on whether Aduro’s pilot plant and Rocket Doctor AI’s payer network keep delivering the kind of checkable, incremental progress that got them noticed in the first place.